Background: Infections with respiratory syncytial virus (RSV) in infancy and early childhood are very common. RSV is the leading cause of bronchiolitis and pneumonia and substantially contributes to the morbidity and mortality of infants and young children worldwide. Until very recently, there have been no vaccines available for prevention and there are no curative treatments for RSV. Two novel pharmaceutical approaches for RSV prevention became available in 2024 namely immunization of mothers during pregnancy and immunoprophylaxis of infants. Since then, a series of scientific papers as well as national and international guidance have been published to encourage parents to vaccinate themselves or their children. Despite strong evidence that breastfeeding is an important non-pharmacological approach for prevention of severe RSV outcomes, recent scientific papers and public health communications have neglected breastfeeding as a core RSV-preventive strategy. This commentary highlights epidemiological evidence of the protective effects of breastfeeding as a key non-pharmacological intervention, discussing its synergistic role in RSV prevention and supportive role in the care of sick infants.
Breastfeeding And Rsv: Breastfeeding has been shown to reduce the rate and severity of RSV-associated outcomes, including hospitalization and mortality. While exclusive breastfeeding is most protective, even one month of breastfeeding was associated with a reduced likelihood of Intensive Care Unit admission and the need of mechanical ventilation in RSV-infected infants. The benefits of breastfeeding for RSV prevention and supportive care have been demonstrated in epidemiological studies in low-, middle- and high-income settings and are especially important for small, premature and sick infants.
Conclusion: Breastfeeding is an overlooked sustainable strategy for the universal prevention of severe outcomes and serves as supportive care of RSV-associated disease in infancy, especially in vulnerable population groups. Breastfeeding should be encouraged alongside vaccines in all public health communication, by health providers during pre- and postnatal immunization visits and during infant check-ups. Further, the role of breastfeeding as supportive care of RSV-infected and critically-ill infants should not be overlooked.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11874759 | PMC |
http://dx.doi.org/10.1186/s13006-025-00705-9 | DOI Listing |
J Infect Dev Ctries
February 2025
Department of Pediatrics Respiratory, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Shandong University, Shandong Provincial Clinical Research Center for Children's Health and Disease office, Jinan, Shandong, 250021, China.
Introduction: The epidemic pattern of the Respiratory syncytial virus (RSV) has changed during the COVID-19 pandemic. To analyze the epidemic pattern of RSV infection and explore the fluctuations of immunity.
Methodology: Pediatric inpatients diagnosed with RSV infection or RSV pneumonia from January 2019 to August 2023 in a tertiary hospital were retrospectively included.
JAMA
March 2025
Department of Veterans Affairs Public Health Reference Laboratory, Palo Alto, California.
Lancet Reg Health West Pac
February 2025
National Centre for Infectious Diseases, Singapore.
Background: More data is required to contextualise respiratory-syncytial-virus (RSV) disease burden, versus other vaccine-preventable respiratory-viral-infections (RVIs) in older adults. We aimed to compare severity of RSV in hospitalized adults versus influenza/boosted COVID-19.
Methods: Retrospective population-based cohort study, including all adult RSV hospitalizations (2021-2023) in Singapore.
Vaccine
March 2025
Pregnancy and Child Health Research Center, HealthPartners Institute, Minneapolis, MN, USA.
Background: Respiratory syncytial virus (RSV) vaccine was recommended for use during pregnancy in September 2023.
Objective: To assess pregnant persons' intentions to receive and evaluate factors associated with RSV vaccine intentions and uptake.
Study Design: We invited 1999 pregnant persons ≥18 years, between 12 and 30 weeks gestation who had received prenatal care at HealthPartners to complete an online survey during September-November 2023.
J Pharm Biomed Anal
February 2025
State Key Laboratory of Vaccines for Infectious Diseases, Xiang An Biomedicine Laboratory, School of Public Health, Xiamen University, Xiamen 361102, China; National Institute of Diagnostics and Vaccine Development in Infectious Diseases, State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, Collaborative Innovation Center of Biologic Products, National Innovation Platform for Industry-Education Integration in Vaccine Research,NMPA Key Laboratory for Research and Evaluation of Infectious Disease Diagnostic Technology, Xiamen University, Xiamen 361102, China; School of Life Sciences, Xiamen University, Xiamen 361102, China. Electronic address:
The co-circulation of respiratory viruses, including SARS-CoV-2, Influenza A (Flu A), Influenza B (Flu B), and respiratory syncytial virus (RSV), poses a significant public health threat. Timely recognition of these viruses allows healthcare professionals to implement effective infection control measures, allocate medical resources properly, and prevent complications from incorrect treatments. Multiplex nucleic acid testing Point-of-care test (mNAT-POCT) circumvents issues of traditional tests, such as high demands on laboratory environments, personnel, and equipment, and limited target analyses, allowing its use in point-of-care settings.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!